FindTrial
Sign In

VTX-2337

DRUG4 trials

Sponsors

Celgene

Conditions

Advanced Solid TumorsCarcinoma, Squamous CellCarcinoma, Squamous Cell of Head and NeckEpithelial Ovarian CancerFallopian Tube CancerLymphomaPrimary Peritoneal Cancer

Phase 1

Safety and Pharmacologic Study of VTX-2337 in Patients With Advanced Cancer
CompletedNCT00688415
CelgeneAdvanced Solid Tumors, Lymphoma
Start: 2008-11-07End: 2010-11-30Updated: 2019-09-25
A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer
TerminatedNCT03906526
CelgeneCarcinoma, Squamous Cell
Start: 2019-07-03End: 2022-01-24Updated: 2023-02-24

Phase 2

VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
CompletedNCT01666444
CelgeneEpithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Start: 2012-10-31End: 2016-07-31Updated: 2019-09-26
Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
CompletedNCT01836029
CelgeneCarcinoma, Squamous Cell of Head and Neck
Start: 2013-10-14End: 2016-09-19Updated: 2019-10-29

Related Papers

Dendritic cell effector mechanisms and tumor immune microenvironment infiltration define TLR8 modulation and PD-1 blockade
Frontiers in Immunology2024-12-043 citations
Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck
JAMA Oncology2018-06-21108 citations
Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN
Clinical Cancer Research2016-11-04125 citations
Abstract AS27: VTX-2337, a TLR8 agonist, plus chemotherapy in recurrent ovarian cancer: preclinical and phase 1 data by the gynecologic oncology group
Clinical Cancer Research2015-08-151 citations